A new study has found beneficial results for patients with relapsed or refractory B-cell lymphoma who took a form of CAR T-cell therapy. The researchers believe the trial demonstrates that CAR-T therapy can be used as a second-line therapy in plac...
1 year ago
First-line ibrutinib combined with venetoclax could benefit patients with high-risk chronic lymphocytic leukaemia (CLL), a new US study has suggested.
A team from Weill Cornell Medicine say fixed duration ibrutinib plus venetoclax led to high resp...
1 year ago
